TY - JOUR
T1 - Serum Circ-DLGAP4 and miR-9 as Potential Biomarkers in Pancreatic Cancer
AU - Ali, Marwa A.
AU - Shaker, Olfat G.
AU - Ezzat, Eman M.
AU - Ahmed, Mohamed Saad Zaghloul
AU - Elasmer, Shimaa Mohammed
AU - Abdelhafeez, Marwa Mamdouh Ahmed
AU - Zaidan, Mohamed
AU - El-Ela, Raghda Yahia Abu
AU - AbdelHafez, Marwa N.
AU - Fares, Eman
AU - Al Abdulqader, Ahmad A.
AU - Awaji, Aeshah A.
AU - Alamoudi, Mariam K.
AU - Abdelaleem, Omayma O.
N1 - Publisher Copyright:
© 2025 The Author(s). Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
PY - 2025/8
Y1 - 2025/8
N2 - Background: Pancreatic cancer remains one of the malignancies characterized by the most insidious onset and dire prognosis. Preliminary diagnostic biomarkers are essential for timely identification and improved prognosis. CircularRNA-DLGAP4 (Circ-DLGAP4) and microRNA-9 (miR-9) are intriguing, easily accessible genetic indicators for numerous diseases. Aim: To quantify serum expression levels of Circ-DLGAP4 and miR-9 in pancreatic cancer patients and juxtapose these values with those of control persons to assess their potential as diagnostic biomarkers. It also aims to correlate their expression levels with the clinicopathological features of the disease. Method: Quantitative analysis of serum samples collected from 40 pancreatic cancer patients and 40 control subjects with RT-PCR. Results: There were statistically significant elevations in blood levels of Circ-DLGAP4 and miR-9 in pancreatic cancer patients compared to healthy persons, with median (range) values of 8.2 (0.39–17.32), p-value < 0.001, and 9.5 (4.06–14.7), respectively. The blood level of Circ-DLGAP4 exhibited a significant positive correlation with the serum concentration of miR-9 (r = 0.89, p = 0.001). Conclusions: Circ-DLGAP4 and miR-9 serve as diagnostic biomarkers for pancreatic cancer.
AB - Background: Pancreatic cancer remains one of the malignancies characterized by the most insidious onset and dire prognosis. Preliminary diagnostic biomarkers are essential for timely identification and improved prognosis. CircularRNA-DLGAP4 (Circ-DLGAP4) and microRNA-9 (miR-9) are intriguing, easily accessible genetic indicators for numerous diseases. Aim: To quantify serum expression levels of Circ-DLGAP4 and miR-9 in pancreatic cancer patients and juxtapose these values with those of control persons to assess their potential as diagnostic biomarkers. It also aims to correlate their expression levels with the clinicopathological features of the disease. Method: Quantitative analysis of serum samples collected from 40 pancreatic cancer patients and 40 control subjects with RT-PCR. Results: There were statistically significant elevations in blood levels of Circ-DLGAP4 and miR-9 in pancreatic cancer patients compared to healthy persons, with median (range) values of 8.2 (0.39–17.32), p-value < 0.001, and 9.5 (4.06–14.7), respectively. The blood level of Circ-DLGAP4 exhibited a significant positive correlation with the serum concentration of miR-9 (r = 0.89, p = 0.001). Conclusions: Circ-DLGAP4 and miR-9 serve as diagnostic biomarkers for pancreatic cancer.
KW - Circ-DLGAP4
KW - miR-9
KW - pancreatic carcinoma
UR - http://www.scopus.com/inward/record.url?scp=105011842366&partnerID=8YFLogxK
U2 - 10.1002/jcla.70076
DO - 10.1002/jcla.70076
M3 - Article
AN - SCOPUS:105011842366
SN - 0887-8013
VL - 39
JO - Journal of Clinical Laboratory Analysis
JF - Journal of Clinical Laboratory Analysis
IS - 16
M1 - e70076
ER -
